France Depression Therapeutics Market Report 2022 to 2030

France Depression Therapeutics Market Analysis

$ 3999

The France depression therapeutics market is expected to witness growth from $278 Mn in 2022 to $386 Mn in 2030 with a CAGR of 4.2% for the forecasted year 2022-2030. The rising incidence of depression and the development of several innovative treatments for depression in France are the major market drivers. The France depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Pharmaleads, Elaiapharm, and AbbVie are the major players in the France depression therapeutics market.

ID: IN10FRPH034 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Dr. Parul Choudhary

Buy Now

France Depression Therapeutics Market Executive Analysis

The France depression therapeutics market size is at around $278 Mn in 2022 and is projected to reach $386 Mn in 2030, exhibiting a CAGR of 4.2% during the forecast period. The French pharmaceutical industry has criticized government plans to establish a 2023 spending cap on medications that is 7% less than the actual 2022 spending. To reduce the cost of prescription drugs by $1.1 Bn in 2019, the government is also preparing several price reductions for medications as well as an increase in what the industry association Leem refers to as a "confiscatory" sales tax. According to the social security funding bill for 2023, the total state spending on reimbursed medications in 2023 is expected to be no more than $26 Bn, down from an anticipated $28 Bn for this year.

A depressive phase could happen to 5% to 15% of French people at some point in their lives. The majority of people who seek mental healthcare do so because of depression, which accounts for more than a quarter of the disease burden connected with mental illnesses. The first-line treatment for these disorders in primary care environments, according to national health authority guidelines, should be psychotherapy, which can be given by general practitioners (GP) directly or by referring patients to a psychiatrist or a psychologist. The main approaches range from structured psychotherapies, which include specific therapy techniques like cognitive-behavioural therapy (CBT), psychodynamic therapy, interpersonal therapy, and family therapy, to supportive psychotherapy, which is a non-directive relational therapy based on empathy, trust, and support with active listening from the therapist. An efficient form of therapy is antidepressants. Some people, particularly children, teenagers, and young adults, may be at risk from them. Antidepressants are not typically the first therapy option for adolescents, nor are they typically prescribed for children. When taking antidepressants for the first time, some individuals may experience negative side effects.

France Depression Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

In France, the frequency of depression is rising, which is driving up the demand for antidepressant medications. More than 3 Mn individuals in France suffer from depression, according to the World Health Organization (WHO). The progress of several pioneering depression therapeutics is expected to stimulate market expansion in the forthcoming years. For example, new drugs that target the glutamate pathway are being industrialized, which may present a different method for treating depression. The French government has started several agendas to enhance mental health care and ease the stigma attached to mental disease. This is predicted to improve the availability of depression treatments and shoot the France depression therapeutics market expansion.

Market Restraints

It can be challenging and laborious for pharmaceutical companies to get novel depression therapeutics sanctioned for sale due to France's strict drug protocols. This might smother the France depression therapeutics market expansion and delay the release of novel medications. The French government has put cost-control mechanisms in place for the drugs, which may have an influence on the cost and financial feasibility of depression treatments. As a result, it might be less tempting for pharmaceutical companies to spend money on producing novel medications for the French market.

Competitive Landscape

Key Players

Ariana Pharmaceuticals (FRA)
Adare Pharmaceuticals (FRA)
Nextpharma (FRA)
Pharmaleads (FRA)
Elaiapharm (FRA)
AbbVie
AstraZeneca
Bristol-Myers Squibb
Cipla
Eli Lily
GlaxoSmithKline
Johnson & Johnson

Healthcare Policies and Regulatory Landscape

The national health insurance system in France, which is supported by both companies and workers, pays for the treatment of depression. The rate of some depression treatments and medications is also covered by the government. The national health insurance program covers antidepressants, but patients are usually obligated to cover a co-payment of about 30% of the drug's charge. However, the co-payment may be mounted back or waived totally for patients with chronic conditions. Government reimbursement for some antidepressants differs, but they are usually older, generic drugs. The government health insurance program also covers psychotherapy in addition to prescription medications. Cognitive-behavioural therapy, interpersonal therapy, and psychodynamic therapy are just a few of the different treatment options accessible to patients. Patients might be required to pay out-of-pocket for additional therapy sessions because the national health insurance system only covers a certain number of sessions. The national health insurance system does not recompense for alternate treatments for depression, such as acupuncture and hypnotherapy, so individuals are responsible for the out-of-pocket costs.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Depression Therapeutics Segmentation

By Drug Type (Revenue, USD Billion):

Antidepressants
Anxiolytics
Anticonvulsants
Noradrenergic Agents
Atypical Antipsychotics

By Therapies (Revenue, USD Billion):

Electroconvulsive Therapy (ECT)
Cognitive Behaviour Therapy (CBT)
Psychotherapy
Deep Brain Stimulation
Transcranial Magnetic Stimulation (TMS)
Cranial electrotherapy stimulation (CES)

By Indication (Revenue, USD Billion):

Major Depressive Disorder (MDD)
Bipolar Disorder
Dysthymic Disorder
Postpartum Depression
Seasonal Affective Disorder (SAD)
Premenstrual Dysphoric Disorder (PMDD)
Others

By End Users (Revenue, USD Billion):

NGOs
Asylums
Hospitals
Mental Healthcare Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.